A drug created and manufactured by Advancer Enterprises, it entered Advancer's pharmaceutical catalog in late YE 45. Oriemelin is a complex anti-radiation medication, designed to counteract the harmful effects of ionizing radiation.

The inception of Oriemelin was driven by escalating concerns about radiation exposure from both natural and anthropogenic sources. Advancer Enterprises, recognizing the urgency of the situation, initiated a specialized project to develop a potent, yet minimally invasive, anti-radiation medication. The development process involved a multi-disciplinary approach, incorporating molecular biology, pharmacology, and clinical research. After years of rigorous testing and refinements, Oriemelin was submitted for Imperial approval in late YE 45.

Oriemelin operates on a molecular level, binding to DNA structures and thereby shielding them from ionizing radiation. This action prevents the formation of free radicals, which are a primary cause of radiation-induced cellular damage. The drug is particularly effective in mitigating the acute symptoms of radiation sickness and reducing the long-term risk of radiation-induced cancers.

The standard dosage for Oriemelin is a 500 mg tablet, administered orally every 12 hours. This regimen should be followed for a maximum of 5 days post-radiation exposure to ensure optimal efficacy and minimize potential side effects. The drug is priced at 35 KS per tablet, with a standard bottle containing 10 tablets priced at 350 KS.

While Oriemelin is generally well-tolerated, it can cause some side effects such as nausea, dizziness, and fatigue. These are usually transient and resolve as the body adjusts to the medication. A more serious concern is the potential for neutropenia, a decrease in white blood cell count, which could render the body more susceptible to infections. Regular blood monitoring is advised during the course of treatment.

An overdose of Oriemelin is considered to be an intake of more than 2000 mg within a 12-hour period. Such an overdose can significantly exacerbate neutropenia, making the individual highly vulnerable to bacterial and viral infections. Immediate medical intervention is required, which may include the administration of broad-spectrum antibiotics or antivirals as a preventive measure against potential infections.

Demibear created this article on 2023/10/09 23:32.

Approval Thread: https://stararmy.com/roleplay-forum/threads/advancer-enterprises-white-lion-type-45-vehicle-aid-kit.71051/